PF-06372865: Clinical Trials

10 completed, 2 terminated, 1 withdrawn. 8 Phase 1, 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	8	Completed 7, Withdrawn 1
Phase 2	5	Completed 3, Terminated 2

Follow PF-06372865: new trials by email Literature Review of PF-06372865 trials Research Report on PF-06372865

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants [14C]-darigabat - Healthy Participants	Phase 1	Completed	Cerevel Therapeutics, LLC	8	2024-05-29	2024-07-31
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures CVL-865 - Seizures	Phase 2	Terminated	AbbVie	105	2020-12-08	2025-12-11
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures Placebo, CVL-865 - Seizures	Phase 2	Completed	AbbVie	154	2020-01-27	2025-05-30
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects Placebo, PF-06372865 - Healthy Volunteers	Phase 1	Completed	Pfizer	19	2017-11-08	2019-06-03
PF-06372865 in Subjects With Photosensitive Epilepsy PF-06372865, Placebo, Lorazepam - Reflex Epilepsy, Photosensitive	Phase 2	Completed	Pfizer	7	2015-12-16	2018-03-14
An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects PF-06372865, itraconazole - Healthy	Phase 1	Withdrawn	Pfizer		2015-07-01	2017-06-26
POC Study in Partially Responsive Generalized Anxiety Disorder PF-06372865. - Generalized Anxiety Disorder	Phase 2	Terminated	Pfizer	90	2014-11-01	2017-01-09
PF-06372865 In Subjects With Chronic Low Back Pain PF-06372865, Placebo, Naproxen - Chronic Low Back Pain	Phase 2	Completed	Pfizer	302	2014-10-01	2017-01-04
Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints PF-06372865 (65mg), PF-06372865 (15mg), Pregabalin - Healthy	Phase 1	Completed	Pfizer	20	2014-09-01	2014-12-16
Food Effect Study for PF-06372865 PF-06372865 - Healthy	Phase 1	Completed	Pfizer	12	2014-09-01	2014-10-27
A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865 PF-06372865 - Healthy	Phase 1	Completed	Pfizer	5	2014-05-01	2014-09-25
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2) PF-06372865, Placebo - Healthy	Phase 1	Completed	Pfizer	50	2014-03-01	2014-08-18
A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865 PF-06372865 or Placebo, PF-06372865 or Placebo or Lorazepam - Healthy	Phase 1	Completed	Pfizer	45	2013-10-01	2014-08-18

Conditions studied

Epilepsies, Partial (2)  ·  Seizures (2)  ·  Epilepsy, Reflex (1)  ·  Generalized Anxiety Disorder (1)  ·  Pain (1)

Sponsors

Pfizer (10)  ·  AbbVie (2)  ·  Cerevel Therapeutics, LLC (1)

Countries

United States (9)  ·  Australia (2)  ·  Belgium (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Serbia (2)  ·  South Korea (2)  ·  Spain (2)  ·  Ukraine (2)

Results publications

PMID 35965432, PMID 29721364, PMID 30877186

NIH funding

2014 (2), 2019 (2)